Adial Pharmaceuticals (ADIL) Assets Average (2018 - 2026)
Adial Pharmaceuticals (ADIL) posted Assets Average of $6.0 million for Q1 2026, down 3.51% sequentially from $6.2 million in Q4 2025, and up 40.09% YoY from $4.2 million in Q1 2025.
Adial Pharmaceuticals (ADIL) Assets Average (2018 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Assets Average for 9 years, with the latest figure at $6.0 million in Q1 2026.
- Quarterly Assets Average rose 40.09% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (up 40.09% YoY) and the FY2025 annual result came in at $6.2 million, up 4.9% from the prior year.
- Assets Average slipped to $6.0 million in Q1 2026 per ADIL's latest filing, from $6.2 million in the prior quarter.
- Over five years, Assets Average peaked at $12.4 million in Q2 2022 and troughed at $3.3 million in Q3 2023.
- A 5-year average of $6.2 million and a median of $5.8 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2024: Assets Average slumped 69.14% in 2023, then soared 75.46% in 2024.
- Over 5 years, Assets Average stood at $6.7 million in 2022, then slumped by 43.57% to $3.8 million in 2023, then surged by 54.61% to $5.9 million in 2024, then increased by 4.9% to $6.2 million in 2025, then retreated by 3.51% to $6.0 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $6.0 million, $6.2 million, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 19.82 Bn |
| 10 | Adial Pharmaceuticals | 27.64 Mn | 27.64 Mn | - | 17.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.95 Mn |
| Dec 31, 2025 | 6.17 Mn |
| Sep 30, 2025 | 6.23 Mn |
| Jun 30, 2025 | 5.13 Mn |
| Mar 31, 2025 | 4.25 Mn |
| Dec 31, 2024 | 5.88 Mn |
| Sep 30, 2024 | 5.83 Mn |
| Jun 30, 2024 | 5.82 Mn |
| Mar 31, 2024 | 5.71 Mn |
| Dec 31, 2023 | 3.80 Mn |
| Sep 30, 2023 | 3.32 Mn |
| Jun 30, 2023 | 3.84 Mn |
| Mar 31, 2023 | 4.82 Mn |
| Dec 31, 2022 | 6.74 Mn |
| Sep 30, 2022 | 9.33 Mn |
| Jun 30, 2022 | 12.44 Mn |
| Mar 31, 2022 | 10.72 Mn |
| Dec 31, 2021 | 8.96 Mn |
| Sep 30, 2021 | 9.25 Mn |
| Jun 30, 2021 | 8.34 Mn |